文献速递骨质疏松与钙磷/甲状旁腺性腺与生殖内分泌

雌激素给药途径对月经稀发运动员骨转换标志物的影响及其中介因素

Impact of Route of Estrogen Administration on Bone Turnover Markers in Oligoamenorrheic Athletes and Its Mediators.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

经皮贴片不引起口服炔雌醇所致的IGF-1下降,并降低硬化蛋白、Pref-1和BDNF,这些变化可能介导雌激素对骨密度的益处。

要点

  • 经皮17β-雌二醇不引起口服炔雌醇所致的IGF-1下降。
  • 经皮贴片组硬化蛋白、Pref-1和BDNF下降。
  • PILL组P1NP下降最多,与IGF-1下降相关(r=0.37,P=0.003)。

核心结论

  • 经皮17β-雌二醇治疗12个月不引起口服炔雌醇所致的IGF-1下降。
  • 经皮雌激素降低硬化蛋白、Pref-1和BDNF,可能介导其对骨密度的有益作用。

主要发现

  • P1NP在PILL组下降最多(P=0.03),且与IGF-1下降相关(r=0.37;P=0.003)。
  • PATCH组硬化蛋白、Pref-1和BDNF在12个月内下降。
  • PATCH组雌二醇增幅最大(P≤0.0001),雌二醇增加与骨密度增加相关。

临床怎么用

  • 对月经稀发运动员,经皮雌激素可能优于口服炔雌醇以保留IGF-1并改善骨转换标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Transdermal, but not oral, estrogen replacement improves bone mineral density (BMD) in athletes with oligoamenorrhea (OA). Our objective was to determine mechanisms that may explain the impact of route of estrogen administration on bone outcomes. METHODS: Seventy-three participants with OA between 14 and 25 years old received (i) a 17β-estradiol transdermal patch continuously with cyclic oral micronized progesterone (PATCH), (ii) a combined ethinyl estradiol and desogestrel pill (PILL), or (iii) no estrogen/progesterone (NONE) for 12 months. We evaluated morning fasting levels of a marker of bone formation [N-terminal propeptide of type 1 procollagen (P1NP)], a marker of bone resorption (N-telopeptide), IGF-1, insulinlike growth factor binding protein 3, total testosterone, estradiol, SHBG, sclerostin, preadipocyte factor-1 (Pref-1), brain-derived neurotrophic factor (BDNF), calcium, 25(OH) vitamin D, and PTH levels at baseline and 12 months. RESULTS: Groups did not differ for age, weight, exercise activity, or markers of bone formation at baseline. Over 12 months, P1NP decreased the most in the PILL group (P = 0.03) associated with a decrease in IGF-1 levels (r = 0.37; P = 0.003). Sclerostin, Pref-1, and BDNF decreased in the PATCH group over 12 months. PATCH had the greatest increases in estradiol (P ≤ 0.0001), and estradiol increases were associated with increases in bone density. CONCLUSION: Transdermal 17β-estradiol given over 12 months does not cause the decrease in IGF-1 observed with oral ethinyl estradiol. It also leads to decreases in sclerostin, Pref-1, and BDNF, which may mediate the beneficial effects of estrogen.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Singhal V, Ackerman KE, Bose A, et al. Impact of Route of Estrogen Administration on Bone Turnover Markers in Oligoamenorrheic Athletes and Its Mediators. J Clin Endocrinol Metab. 2019. PMID: 30476179. doi:10.1210/jc.2018-02143

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。